triazoles has been researched along with Nasopharyngitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abi-Saab, W; Besuyen, R; Coates, LC; Dudek, A; Gladman, DD; Greer, JM; Harrison, P; Helliwell, PS; Kunder, R; Mease, P; Meuleners, L; Mozaffarian, N; Rychlewska-Hanczewska, A; Stanislavchuk, M; Tasset, C; Van den Bosch, F; Van der Aa, A | 1 |
| Abi-Saab, W; Baraliakos, X; Besuyen, R; Deodhar, A; Gensler, LS; Greer, JM; Hendrikx, T; Landewé, R; Liu, K; Maksymowych, WP; Meuleners, L; Mozaffarian, N; Nadashkevich, O; Tasset, C; Tseluyko, V; van der Heijde, D | 1 |
2 trial(s) available for triazoles and Nasopharyngitis
| Article | Year |
|---|---|
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Topics: Accidental Falls; Antirheumatic Agents; Arthritis, Psoriatic; Double-Blind Method; Drug Therapy, Combination; Female; Headache; Hip Fractures; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Male; Middle Aged; Nasopharyngitis; Opportunistic Infections; Pneumonia; Pyridines; Severity of Illness Index; Triazoles | 2018 |
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
Topics: Adult; Antirheumatic Agents; Double-Blind Method; Female; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Male; Middle Aged; Nasopharyngitis; Opportunistic Infections; Pneumonia; Pyridines; Severity of Illness Index; Spondylitis, Ankylosing; Treatment Outcome; Triazoles | 2018 |